Ketamine clinics advertising false, misleading health claims: Study
IANS 09 November 2023
Hundreds of clinics may be using false and misleading statements in online advertising campaigns by offering off-label and unapproved ketamine to treat a variety of mental health and pain conditions, according to researchers.
In the study published in JAMA Network Open, the researchers noted that intravenous ketamine is not approved by the US FDA to treat any mental health condition but is sometimes used off-label for it. 
Oral formulations are unapproved drugs that are often advertised to produce a hallucinogenic experience at home.
"These are expensive treatments for which patients generally must pay out of pocket and the evidence base is often not robust for many of the advertised uses," said Michael DiStefano, Assistant Professor in the Department of Clinical Pharmacy at the University of Colorado Anschutz Medical Campus. 
"It is important that people considering these treatments are provided with an accurate and balanced statement of the possible risks and benefits," he added.
For the study, the team identified online direct-to-consumer ketamine advertisers with at least one clinic in Maryland and a website by using six national ketamine databases.
They found 17 advertisers operating across 26 locations in Maryland that promoted infusions or ketamine assisted therapy for a wide range of conditions including depression, post-traumatic stress disorder (PTSD), anxiety and chronic pain. The advertising revealed numerous misleading representations regarding treatment and safety.
While the study focused on clinics in Maryland, DiStefano said their compilation of the six directories for ketamine treatment suggests that there are approximately 800 such clinics across the US. He said there are also several companies that will send customers oral ketamine through the mail.
"Psychedelic or hallucinogenic substances are increasingly being considered as mental health treatments. For example, Colorado is at the vanguard of developing policies to govern the use of psilocybin in depression." DiStefano said.
"It is important to be transparent and accurate when explaining the potential risks and benefits of these treatments. While these treatments can provide hope and will be effective for some patients, there are real risks associated with ketamine use, especially over the long-term. There are high financial costs to consider as well."
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.
Take 8,000 Steps Daily To Reduce Risk of Premature Death
Akshay Naik 03 November 2023
The benchmark of taking 10,000 steps a day has no proven scientific basis and yet it continues to remain a daily goal for many fitness enthusiasts. Now, a new study has provided scientific evidence to show that most benefits of...
Antibiotics now ineffective for common childhood infections: Lancet
IANS 01 November 2023
High rates of antibiotic resistance have rendered the drugs used to treat common infections in children and babies, ineffective, according to an alarming study published in Lancet South East Asia on Tuesday.
The University...
Even More Reasons To Add Fibre to Your Diet
Akshay Naik 27 October 2023
The benefits of insoluble fibre, for bowel regularity and overall health, have been known and highly praised by health professionals. New research now suggests even more reasons to prioritise fibre in our regular...
US report finds 'concerning' levels of lead, cadmium in chocolates; top trade body responds
IANS 26 October 2023
After US-based non-profit group Consumer Reports alleged it detected a "concerning" amount of lead and cadmium in popular chocolate brands during tests, the National Confectioners Association (NCA) has said that "chocolate and cocoa...
Free Helpline
Legal Credit